Edesa生物技术 EDSA 深 沪
等待开盘 03-26 09:30:00 美东时间
6.57
-0.450
-6.41%
华盛通- 最 高6.95
- 今 开6.76
- 成交量 52.57万股
- 最 低 6.12
- 昨 收 7.02
- 总市值 5484.74万
- 52周最高 9.37
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 0.72
- 委 比 -44.84%
- 总股本 834.82万
- 历史最高 133.70
- 量 比 0.42
- 振 幅 11.82%
- 历史最低 0.72
- 每 手 1
- 风险率 1.18%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Why Box Shares Are Trading Higher By Over 6%; Here Are 20 Stocks Moving Premarket
Box Inc (BOX) shares jump 6.2% in pre-market trading after beating earnings expectations with $305.88M in revenue and 49 cents per share earnings.
03-04 17:43
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Edesa Biotech (NASDAQ:EDSA) shares rose 61.0% to $3.67 during Tuesday'...
03-04 01:05
Why Axon Enterprise Shares Are Trading Higher By Over 16%; Here Are 20 Stocks Moving Premarket
Shares of Axon Enterprise Inc (NASDAQ:AXON) rose sharply in pre-market trading ...
02-25 17:22
Edesa Biotech Announces Additional Data From Phase 3 Study Of Paridiprubart
Results in a population of 278 patients affirm statistically significant mortality reductionsBenefits observed across severity groups and in subjects with serious comorbiditiesCompany files provisional patent
02-24 22:16
Edesa Biotech Q1 EPS $(0.28) Beats $(0.45) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.45) by 37.78 percent. This is a 41.67 percent increase over losses of $(0.48) per share from the
02-14 05:20
Edesa Biotech Q4 EPS $(0.32) Misses $(0.27) Estimate
Edesa Biotech (NASDAQ:EDSA) reported quarterly losses of $(0.32) per share which missed the analyst consensus estimate of $(0.27) by 19.85 percent. This is a 10.34 percent decrease over losses of $(0.29) per share from
2025-12-13 05:23
12 Health Care Stocks Moving In Friday's After-Market Session
Gainers MSP Recovery (NASDAQ:MSPR) stock increased by 36.4% to $0.3 during Fri...
2025-11-01 05:07
Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study
Edesa Biotech announced positive Phase 3 results for paridiprubart in treating ARDS, showing a 25% relative reduction in mortality risk and a 41% higher rate of clinical improvement. The drug met primary and secondary endpoints, demonstrated durable survival benefits, and was well-tolerated. It has potential for standard-of-care treatment in ARDS and chronic respiratory conditions, supported by funding from the Canadian government.
2025-10-28 11:45
Edesa Biotech and InflaRx: Breathing New Life into ARDS Treatment
Edesa Biotech (($EDSA)), Inflarx N.V. (($IFRX)) announced an update on their on...
2025-10-28 07:50
Edesa Biotech Amends Agreement with Canadian Government
Edesa Biotech ( ($EDSA) ) has issued an announcement. On September 30, 2025, Ed...
2025-10-01 04:27
